Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ECOR 
Electrocore LLC (ECOR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ECOR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 7.56% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 44.53M USD | Price to earnings Ratio - | 1Y Target Price 25.2 |
Price to earnings Ratio - | 1Y Target Price 25.2 | ||
Volume (30-day avg) 208485 | Beta 0.25 | 52 Weeks Range 5.32 - 19.49 | Updated Date 04/1/2025 |
52 Weeks Range 5.32 - 19.49 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.59 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-11 | When Before Market | Estimate -0.3 | Actual -0.4 |
Profitability
Profit Margin -47.2% | Operating Margin (TTM) -43.59% |
Management Effectiveness
Return on Assets (TTM) -41.57% | Return on Equity (TTM) -158.63% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 36692240 | Price to Sales(TTM) 1.91 |
Enterprise Value 36692240 | Price to Sales(TTM) 1.91 | ||
Enterprise Value to Revenue 1.53 | Enterprise Value to EBITDA 0.16 | Shares Outstanding 7193090 | Shares Floating 5963649 |
Shares Outstanding 7193090 | Shares Floating 5963649 | ||
Percent Insiders 23.64 | Percent Institutions 12.63 |
Analyst Ratings
Rating 4.6 | Target Price 25.47 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Electrocore LLC
Company Overview
History and Background
Electrocore, LLC is a commercial-stage bioelectronic medicine company focused on non-invasive vagus nerve stimulation (nVNS) therapy. Founded to develop and commercialize its gammaCore device, its evolution has centered around expanding indications and market reach.
Core Business Areas
- nVNS Therapy: Development and commercialization of non-invasive vagus nerve stimulation therapy for various conditions.
- GammaCore Device: Sales and distribution of the gammaCore device, a handheld nVNS device.
- Research and Development: Ongoing research to expand the applications of nVNS therapy to new medical conditions.
Leadership and Structure
Electrocore's leadership team typically includes a CEO, CFO, and other executives responsible for overseeing operations, finance, and strategy. The organizational structure involves departments for research, development, sales, and marketing.
Top Products and Market Share
Key Offerings
- GammaCore Sapphire: A non-invasive vagus nerve stimulation (nVNS) therapy device used to treat migraine and cluster headache. Market share data for nVNS is difficult to obtain with precision, but they are a prominent player in the early stages of the nVNS market. Competitors include neuromodulation companies with other types of stimulators that aim to treat similar disorders, like Cefaly and others in the neuromodulation space.
- GammaCore nVNS for Acute Migraine: Specifically targeted for acute migraine treatment. Market share is difficult to pinpoint as the nVNS market is nascent, but they aim to become a leading therapy in the migraine sector. Competitors include pharmaceutical interventions, neuromodulation devices, and alternative treatments.
Market Dynamics
Industry Overview
The neuromodulation industry is growing, driven by increasing awareness of alternative therapies and technological advancements. Non-invasive stimulation is a rapidly expanding segment.
Positioning
Electrocore is positioned as an innovator in the nVNS space, offering a non-pharmacological treatment option for neurological disorders. Their competitive advantage lies in their proprietary technology and focus on nVNS.
Total Addressable Market (TAM)
The TAM for neuromodulation is estimated to be in the billions of dollars. Electrocore is positioned to capture a significant portion of this market with continued adoption of their nVNS therapy. Estimate 8 to 10 Billion USD.
Upturn SWOT Analysis
Strengths
- Proprietary nVNS technology
- FDA cleared for multiple indications
- Non-pharmacological treatment option
- Growing body of clinical evidence
Weaknesses
- Limited market adoption compared to pharmaceuticals
- High device cost
- Dependence on insurance reimbursement
- Relatively small company size
Opportunities
- Expanding indications for nVNS therapy
- Partnerships with healthcare providers and insurers
- Increasing awareness of non-pharmacological treatments
- Global market expansion
Threats
- Competition from pharmaceutical companies
- Changes in healthcare regulations
- Economic downturn affecting healthcare spending
- Technological advancements leading to competing devices
Competitors and Market Share
Key Competitors
- CRMD
- BSX
- STIM
Competitive Landscape
Electrocore's advantage lies in its nVNS technology, while its disadvantages include limited resources and market presence compared to larger, established competitors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are not available due to the company's private status.
Future Projections: Future growth projections are not publicly available.
Recent Initiatives: Recent initiatives could include expansion into new geographic markets, development of new product applications, or strategic partnerships.
Summary
Electrocore LLC is an innovator in the nVNS space, but its status as a private company limits available information. Its strength lies in its proprietary technology, but faces challenges related to adoption and competition. Success depends on expanding indications, securing reimbursement, and managing competition effectively.
Similar Companies
BSX
Boston Scientific Corp
BSX
Boston Scientific Corp
CRMD
CorMedix Inc
CRMD
CorMedix Inc
STIM
Neuronetics Inc
STIM
Neuronetics Inc
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- News articles
- Analyst reports (when available)
Disclaimers:
Data is based on publicly available information and may not be entirely accurate or up-to-date. The analysis is for informational purposes only and should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Electrocore LLC
Exchange NASDAQ | Headquaters Rockaway, NJ, United States | ||
IPO Launch date 2018-06-22 | CEO & Director Mr. Daniel S. Goldberger | ||
Sector Healthcare | Industry Medical Devices | Full time employees 73 | Website https://www.electrocore.com |
Full time employees 73 | Website https://www.electrocore.com | ||
electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.